Dexcom, Inc.

Dexcom, Inc. (often referred to as Dexcom) is an American multinational healthcare company headquartered in San Diego, California, founded in 1999. It is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol DXCM, and is a component of both the Nasdaq-100 and S&P 500. As of 2025, Dexcom reported approximately 11,100 employees and an estimated revenue of US$4.66 billion.

Dexcom specializes in the design, development, manufacture, and distribution of continuous glucose monitoring (CGM) systems for diabetes management. Their primary product lines include the Dexcom G6 and G7 CGM systems, which provide real-time glucose readings to compatible smart devices or receivers, eliminating the need for routine fingerstick blood glucose testing for many users. They also offer the Stelo Glucose Biosensor System, an over-the-counter option for adults with Type 2 diabetes not on insulin. These systems help users and healthcare professionals monitor glucose levels, detect trends, and make informed treatment decisions.

Based on the provided case data, Dexcom, Inc. demonstrates the litigation posture of an operating company defending against patent infringement allegations. The company has been involved in one tracked case, appearing solely as a defendant.

The notable case involving Dexcom is Abbott Diabetes Care Inc. v. Dexcom, Inc., filed in the United States District Court for the District of Delaware on September 20, 2019. This single defendant appearance indicates that Dexcom is primarily focused on protecting its core business and products from intellectual property challenges rather than asserting its own patent portfolio as a plaintiff.